Extracellular vesicles (EVs) are increasingly investigated for delivering nucleic acid (NA)
therapeutics, leveraging their natural role in transporting NA and protein-based cargo in cell …

RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for
treating diverse diseases. However, their potential is commonly hindered by vulnerability to …

ABSTRACT mRNA delivered using lipid nanoparticles (LNPs) has become an important
subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely …

In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor
immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great …

Lipid nanoparticles (LNPs) for nucleic acid delivery often use novel lipids as functional
excipients to modulate the biodistribution, pharmacokinetics, pharmacodynamics and …

Recent investigations into autonomous ingestible microjet devices have demonstrated the
feasibility of delivering many drug modalities directly into the gastrointestinal (GI) wall via the …

The prolonged retention of ionizable lipids within the body limits the repeated dosing of lipid
nanoparticles (LNPs) for nucleic acid delivery. While most ionizable lipids are primarily …

The messenger RNA (mRNA) platform emerged at the forefront of vaccine development
during the COVID-19 pandemic, with two mRNA COVID-19 vaccines being among the first …

Aim: Increased knowledge of biodistribution and pharmacokinetics of lipid nanoparticle
(LNP)-encapsulated mRNA drug components may aid efficacy and safety evaluation …

SARS-CoV-2 spread rapidly across the globe, contributing to the death of millions of
individuals from 2019 to 2023, and has continued to be a major cause of morbidity and …